Additional file 3: Table S3. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Additional file 2: of Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

Takuya Osada (81103)
Zachary Hartman (5618339)
Junping Wei (5157695)
Gangjun Lei (5618342)
Amy Hobeika (81102)
William Gwin (5618345)
Marcio Diniz (5392709)
Neil Spector (29266)
Timothy Clay (4111156)
Wei Chen (23863)
Michael Morse (3526097)
H. Lyerly (5618348)

August 2018

Table S1. Epitope mapping of HER3-VIA using spotted 15-mer peptide arrays. Epitope mapping was perfo...

Additional file 1: Table S1. of A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Amabel Tan (302589)
Anne Goubier (3541961)
Holbrook Kohrt (3541958)

November 2015

Vaccine categories in trial completed prior to 2013, or with planned completion post 2013. Table S2....

Additional file 1 of A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Qingyuan Zhang (435205)
Bin Shao (460997)
Zhongsheng Tong (295022)
Quchang Ouyang (6210956)
Yuting Wang (434390)
Guoying Xu (12829180)
Shaorong Li (3290874)
Huiping Li (617425)

October 2022

Additional file 1: Table S1. Adverse events leading to dose interruption in either group. Table 2. I...

Additional file 1: Table S1. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

Summary of criteria for dose-limiting toxicities (CTCAE version 4.03 grading). Footnote: ALT alanine...

Additional file 4: Figure S1. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

A Baseline NRG1 level in archival tumor samples by treatment group and indication. B Best percentage...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient populati...

Additional file 3: Table S3. of High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Lorenzo Falchi (3466142)
Ahmed Sawas (3466148)
Changchun Deng (57747)
Jennifer Amengual (3466154)
Donald Colbourn (3466130)
Emily Lichtenstein (3466133)
Karen Khan (3466139)
Lawrence Schwartz (3466151)
Owen OâConnor (3466157)

November 2016

Adverse events observed during immune checkpoint inhibitor therapy. (DOCX 15Â kb

Additional file 6: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S2. Effect of trastuzumab on HER2 and HER3 levels. FACS analysis of HER2 and HER3 levels in A...

Additional file 3: of Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Trygve Lofterød (5396501)
Elin Mortensen (5396498)
Hawa Nalwoga (845585)
Tom Wilsgaard (321883)
Hanne Frydenberg (3542120)
Terje Risberg (25586)
Anne Eggen (4100746)
Anne McTiernan (3542132)
Sura Aziz (655431)
Erik Wist (3542126)
Andreas Stensvold (3528713)
Jon Reitan (5396495)
Lars Akslen (4406518)
Inger Thune (315574)

June 2018

Figure S2. Age-adjusted breast cancer-free interval by breast cancer molecular subtypesa. a Luminal ...

Additional file 10: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S6. Effect of trastuzumab on HER2 protein levels. Western blot analysis of HER2 levels in AU5...

Additional file 1: Table S1. of The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Stefanie de Groot (3585650)
Maaike Vreeswijk (3537473)
Marij Welters (3440804)
Gido Gravesteijn (3585671)
Jan Boei (3585659)
Anouk Jochems (3585656)
Daniel Houtsma (3585665)
Hein Putter (73805)
Jacobus van der Hoeven (3585662)
Johan Nortier (3585653)
Hanno Pijl (123561)
Judith Kroep (3585668)

October 2015

Median of γ-H2AX geomean intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD4...

Additional file 1: of Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

Gaia Griguolo (5042417)
Tomรกs Pascual (6526022)
Maria Dieci (5437085)
Valentina Guarneri (3562331)
Aleix Prat (3530144)

March 2019

Table S1. Summary of prognostic/predictive value of tumor infiltrating lymphocytes (TILs) in HER2+ b...

Additional file 7: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S3. Combinatory treatment with HER3 siRNA and trastuzumab is useful for overcoming trastuzuma...

Additional file 2: of Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Kyriakos Papadopoulos (2134939)
Eytan Ben-Ami (382254)
Amita Patnaik (5599259)
Denise Trone (5599262)
Jianke Li (219587)
George Demetri (3455120)

August 2018

Most common (reported in âĽ2 patients) treatment-emergent adverse events (safety population). (DOCX...

Additional file 3: of From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Júlia Perera-Bel (4968799)
Barbara Hutter (420459)
Christoph Heining (4968805)
Annalen Bleckmann (318840)
Martina Fröhlich (2186257)
Stefan Fröhling (4968802)
Hanno Glimm (200902)
Benedikt Brors (14082)
Tim Beißbarth (31587)

March 2018

Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...

Additional file 2: of Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

Takuya Osada (81103)
Zachary Hartman (5618339)
Junping Wei (5157695)
Gangjun Lei (5618342)
Amy Hobeika (81102)
William Gwin (5618345)
Marcio Diniz (5392709)
Neil Spector (29266)
Timothy Clay (4111156)
Wei Chen (23863)
Michael Morse (3526097)
H. Lyerly (5618348)

August 2018

Table S1. Epitope mapping of HER3-VIA using spotted 15-mer peptide arrays. Epitope mapping was perfo...

Additional file 1: Table S1. of A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Amabel Tan (302589)
Anne Goubier (3541961)
Holbrook Kohrt (3541958)

November 2015

Vaccine categories in trial completed prior to 2013, or with planned completion post 2013. Table S2....

Additional file 1 of A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Qingyuan Zhang (435205)
Bin Shao (460997)
Zhongsheng Tong (295022)
Quchang Ouyang (6210956)
Yuting Wang (434390)
Guoying Xu (12829180)
Shaorong Li (3290874)
Huiping Li (617425)

October 2022

Additional file 1: Table S1. Adverse events leading to dose interruption in either group. Table 2. I...

Additional file 1: Table S1. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

Summary of criteria for dose-limiting toxicities (CTCAE version 4.03 grading). Footnote: ALT alanine...

Additional file 4: Figure S1. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Reynolds (4431211)
Philippe Bedard (362729)
Se-Hoon Lee (73313)
Chia-Chi Lin (1849147)
Josep Tabernero (237681)
Maria Alsina (4431229)
Ezra Cohen (4431199)
JosĂŠ Baselga (4431244)
George Blumenschein (4431226)
Donna Graham (4431205)
Ignacio Garrido-Laguna (160665)
Dejan Juric (4431196)
Sunil Sharma (435513)
Ravi Salgia (253953)
Abdelkader Seroutou (4431223)
Xianbin Tian (2004925)
Rose Fernandez (4431220)
Alex Morozov (4431202)
Qing Sheng (50321)
Thiruvamoor Ramkumar (4431217)
Angela Zubel (4431214)
Yung-Jue Bang (73319)

September 2017

A Baseline NRG1 level in archival tumor samples by treatment group and indication. B Best percentage...

Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Ian Krop (3430586)
Shanu Modi (3568451)
Patricia LoRusso (353749)
Mark Pegram (3568463)
Ellie Guardino (3568457)
Betsy Althaus (3568454)
Dan Lu (135836)
Alexander Strasak (3568460)
Anthony Elias (3449)

March 2016

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient populati...

Additional file 3: Table S3. of High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Lorenzo Falchi (3466142)
Ahmed Sawas (3466148)
Changchun Deng (57747)
Jennifer Amengual (3466154)
Donald Colbourn (3466130)
Emily Lichtenstein (3466133)
Karen Khan (3466139)
Lawrence Schwartz (3466151)
Owen OâConnor (3466157)

November 2016

Adverse events observed during immune checkpoint inhibitor therapy. (DOCX 15Â kb

Additional file 6: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S2. Effect of trastuzumab on HER2 and HER3 levels. FACS analysis of HER2 and HER3 levels in A...

Additional file 3: of Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes

Trygve Lofterød (5396501)
Elin Mortensen (5396498)
Hawa Nalwoga (845585)
Tom Wilsgaard (321883)
Hanne Frydenberg (3542120)
Terje Risberg (25586)
Anne Eggen (4100746)
Anne McTiernan (3542132)
Sura Aziz (655431)
Erik Wist (3542126)
Andreas Stensvold (3528713)
Jon Reitan (5396495)
Lars Akslen (4406518)
Inger Thune (315574)

June 2018

Figure S2. Age-adjusted breast cancer-free interval by breast cancer molecular subtypesa. a Luminal ...

Additional file 10: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S6. Effect of trastuzumab on HER2 protein levels. Western blot analysis of HER2 levels in AU5...

Additional file 1: Table S1. of The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Stefanie de Groot (3585650)
Maaike Vreeswijk (3537473)
Marij Welters (3440804)
Gido Gravesteijn (3585671)
Jan Boei (3585659)
Anouk Jochems (3585656)
Daniel Houtsma (3585665)
Hein Putter (73805)
Jacobus van der Hoeven (3585662)
Johan Nortier (3585653)
Hanno Pijl (123561)
Judith Kroep (3585668)

October 2015

Median of γ-H2AX geomean intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD4...

Additional file 1: of Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

Gaia Griguolo (5042417)
Tomรกs Pascual (6526022)
Maria Dieci (5437085)
Valentina Guarneri (3562331)
Aleix Prat (3530144)

March 2019

Table S1. Summary of prognostic/predictive value of tumor infiltrating lymphocytes (TILs) in HER2+ b...

Additional file 7: of Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Xin Li (51274)
Yuxiu Xu (5581421)
Yun Ding (234322)
Changfei Li (5581424)
Hong Zhao (325)
Jiandong Wang (596249)
Songdong Meng (420605)

August 2018

Figure S3. Combinatory treatment with HER3 siRNA and trastuzumab is useful for overcoming trastuzuma...

Additional file 2: of Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Kyriakos Papadopoulos (2134939)
Eytan Ben-Ami (382254)
Amita Patnaik (5599259)
Denise Trone (5599262)
Jianke Li (219587)
George Demetri (3455120)

August 2018

Most common (reported in âĽ2 patients) treatment-emergent adverse events (safety population). (DOCX...

Additional file 3: of From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

Júlia Perera-Bel (4968799)
Barbara Hutter (420459)
Christoph Heining (4968805)
Annalen Bleckmann (318840)
Martina Fröhlich (2186257)
Stefan Fröhling (4968802)
Hanno Glimm (200902)
Benedikt Brors (14082)
Tim Beißbarth (31587)

March 2018

Percentage of patients of the top ten biomarkers at each level of evidence in each tumor type. Level...

Additional file 2: of Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

Takuya Osada (81103)
Zachary Hartman (5618339)
Junping Wei (5157695)
Gangjun Lei (5618342)
Amy Hobeika (81102)
William Gwin (5618345)
Marcio Diniz (5392709)
Neil Spector (29266)
Timothy Clay (4111156)
Wei Chen (23863)
Michael Morse (3526097)
H. Lyerly (5618348)

August 2018

Table S1. Epitope mapping of HER3-VIA using spotted 15-mer peptide arrays. Epitope mapping was perfo...

Additional file 1: Table S1. of A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Amabel Tan (302589)
Anne Goubier (3541961)
Holbrook Kohrt (3541958)

November 2015

Vaccine categories in trial completed prior to 2013, or with planned completion post 2013. Table S2....

Additional file 1 of A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Qingyuan Zhang (435205)
Bin Shao (460997)
Zhongsheng Tong (295022)
Quchang Ouyang (6210956)
Yuting Wang (434390)
Guoying Xu (12829180)
Shaorong Li (3290874)
Huiping Li (617425)

October 2022

Additional file 1: Table S1. Adverse events leading to dose interruption in either group. Table 2. I...

Additional file 3: Table S3. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Abstract

Extracted data

Additional file 3: Table S3. of A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Abstract

Extracted data

Related items

Related items